Laigo Bio extended its seed round to €17 million as it advances a novel E3 ligase‑based targeted protein degradation platform toward clinical translation. The additional capital will support preclinical validation and IND‑enabling work for degrader candidates, the company said. Laigo’s funding round reflects sustained investor appetite for TPD modalities and the push to convert discovery‑stage targeted degradation programs into first‑in‑human studies.